Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2010
10/28/2010US20100272811 Complex of trospium and pharmaceutical compositions thereof
10/28/2010US20100272810 Delivery System for Binding and Release of Growth Factors
10/28/2010US20100272809 Microparticles comprising somatostatin analogues
10/28/2010US20100272808 Shell-and-Core Dosage Form Approaching Zero-Order Drug Release
10/28/2010US20100272807 Sustained release aminopyridine composition
10/28/2010US20100272806 Compositions and Methods for Treating and Preventing Urolithiasis and Conditions Associated Therewith
10/28/2010US20100272805 Hydrogels for combinatorial delivery of immune-modulating biomolecules
10/28/2010US20100272804 Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
10/28/2010US20100272803 Repair and regeneration of ocular tissue using postpartum-derived cells
10/28/2010US20100272802 Compositions comprising strontium and uses thereof in the treatment or prevention of gingivitis, periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal diseases
10/28/2010US20100272801 Pharmaceutical compositions of amlodipine and valsartan
10/28/2010US20100272800 Orally disintegrating olanzapine tablet
10/28/2010US20100272799 Coating technology to produce a combination solid dosage form
10/28/2010US20100272798 Controlled release preparation
10/28/2010US20100272797 Pharmaceutical Composition for Treating Hepatitis C Virus Infection Comprising HMG-COA Reductase Inhibitor and Bile Acid
10/28/2010US20100272796 Sustained release aminopyridine composition
10/28/2010US20100272795 Sustained release aminopyridine composition
10/28/2010US20100272794 Pharmaceutical composition of memantine
10/28/2010US20100272793 Controlled Release Hydraliazine Formulations
10/28/2010US20100272792 Stability additives for dry dha dosage forms
10/28/2010US20100272791 Composition having effect on treatment and prevention of dry eye syndrome
10/28/2010US20100272790 Methods of Treating Skin
10/28/2010US20100272789 External medicine for treatment or prevention
10/28/2010US20100272788 Vaccines for malaria
10/28/2010US20100272787 Amethod of treating neurodegenerative diseases
10/28/2010US20100272786 Vaccine
10/28/2010US20100272785 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
10/28/2010US20100272783 Methods of Treating Infections of the Nail
10/28/2010US20100272782 Acellular tissue matrix compositions for tissue repair
10/28/2010US20100272781 Sugar Free Chewable Tablets
10/28/2010US20100272779 Progesterone-containing compositions and devices
10/28/2010US20100272777 Ocular therapeutic agent delivery devices and methdos for making and using such devices
10/28/2010US20100272773 Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device
10/28/2010US20100272772 Apparatus, system, and method for creating immunologically enhanced spaces in-vivo
10/28/2010US20100272771 Device including bone cage and method for treatment of disease in a subject
10/28/2010US20100272764 Microencapsulated compositions and methods for tissue mineralization
10/28/2010US20100272763 Skin external preparation and method of producing the same
10/28/2010US20100272762 Freeze-Dried Coated Molded Article
10/28/2010US20100272761 Synthesis of lipoamide-grafted high molecular compound and method therefor
10/28/2010US20100272655 Menthylcarboxamides and Their Use as Cooling Agents
10/28/2010US20100272654 Levalbuterol salt
10/28/2010US20100272643 Procaspase 8-Mediated Disease Targeting
10/28/2010US20100272639 Polysaccharide nanoparticles
10/28/2010US20100272638 Radiolabelled microparticles, processes for the preparation thereof and the use thereof
10/28/2010US20100272637 Compositions emitting positrons and containing inorganic particles, and use thereof in medicine, especially for diagnostic processes
10/28/2010US20100272636 Anti-CD74 Immunoconjugates and Methods of Use
10/28/2010US20100270183 Stable digestive enzyme compositions
10/28/2010US20100269858 Compositions and kits for the removal of irritating compounds from bodily surfaces
10/28/2010US20100269825 Inhalation particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone and a corticosteroid
10/28/2010DE4124468B4 Verfahren zur Gewinnung eines Polylactids in gereinigtem Zustand sowie ein Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung mit den gereinigten Polylactiden A process for obtaining a polylactide in a purified state and a process for preparing a pharmaceutical composition comprising the purified polylactides
10/28/2010CA2792953A1 Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof
10/28/2010CA2759874A1 Methods of treating a pulmonary bacterial infection using fluoroquinolones
10/28/2010CA2759870A1 Particulate pharmaceutical composition with an opioid and an opioid antagonist
10/28/2010CA2759807A1 Controlled release dispensing device
10/28/2010CA2759793A1 Preparation and application of the new antibacterial and anticancer compounds and their derivatives
10/28/2010CA2759730A1 Stable topical compositions for 1,2,4-thiadiazole derivatives
10/28/2010CA2759727A1 Hydrogels for combinatorial delivery of immune-modulating biomolecules
10/28/2010CA2759541A1 Delivery systems
10/28/2010CA2759456A1 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
10/28/2010CA2759244A1 Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof
10/28/2010CA2759127A1 A novel formulation of meloxicam
10/28/2010CA2759125A1 A novel formulation of indomethacin
10/28/2010CA2759123A1 A novel formulation of diclofenac
10/28/2010CA2759122A1 A novel formulation of naproxen
10/28/2010CA2759113A1 A novel formulation of metaxalone
10/28/2010CA2759109A1 Method for the production of commercial nanoparticle and microparticle powders
10/28/2010CA2759108A1 Production of encapsulated nanoparticles at commercial scale
10/28/2010CA2759104A1 Method for improving the dissolution profile of a biologically active material
10/28/2010CA2759102A1 Production of encapsulated nanoparticles at high volume fractions
10/28/2010CA2759060A1 A drug composition for treating tumor with polymeric micelle encapsulating anti-neoplastic
10/28/2010CA2759042A1 Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
10/28/2010CA2759041A1 Agglomerate formulations useful in dry powder inhalers
10/28/2010CA2758714A1 Tablet and pestle therefor
10/28/2010CA2758618A1 Particulate material for controlled release of active ingredients
10/28/2010CA2756925A1 Sublingual spray formulation comprising dihydroartemesinin
10/28/2010CA2756879A1 Sublingual pharmaceutical composition comprising a neutral oil
10/28/2010CA2756340A1 Bear bile extract and preparation method and use thereof
10/28/2010CA2755328A1 Use of nifuratel to treat infections caused by atopobium species
10/27/2010EP2243506A2 External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
10/27/2010EP2243495A1 A drug delivery system, its preparation process and use
10/27/2010EP2243490A1 Insulin nasal powder inhalation
10/27/2010EP2243487A1 Enteric coated formulation
10/27/2010EP2243484A2 Controlled release oxycodone compositions
10/27/2010EP2243483A1 Amlodipine salt compositions for topical application
10/27/2010EP2243477A1 Paracetamol for parenteral application
10/27/2010EP2243475A1 Combination of memantine and donepezil for treatment of CNS disorders
10/27/2010EP2243473A1 Tablets comprising a taste masking agent
10/27/2010EP2243472A1 Freeze-dried agent compound
10/27/2010EP2243471A1 Matrix for sustained, invariant and independent release of active compounds
10/27/2010EP2243470A1 Freeze-dried coated moulded body
10/27/2010EP2243469A1 Freeze-dried form body containing magnesium ascorbyl phosphate
10/27/2010EP2243468A1 Orally Disintegrating Dimebolin Compositions
10/27/2010EP2242514A2 Intralymphatic chemotherapy drug carriers
10/27/2010EP2242507A1 Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
10/27/2010EP2242486A1 Encapsulation of vitamin c into water soluble dendrimers
10/27/2010EP2242485A2 Oral controlled release tablet
10/27/2010EP2242484A1 Sustained release dosage form for lubricating an oral cavity
10/27/2010EP2242483A1 Raloxifene composition
10/27/2010EP2242482A2 Anti - retroviral combination
10/27/2010EP2242481A1 Article and method for focused delivery of therapeutic and/or diagnostic materials
1 ... 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 ... 2991